Clinical trial NCT03076372: A Study Evaluating MM-310 in Patients With Solid Tumors
Official title: A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Solid Tumors
Urothelial Carcinoma
Gastric Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Ovarian Cancer
Pancreatic Ductal Adenocarcinoma
Prostate Adenocarcinoma
Non-small Cell Lung Cancer
Small Cell Lung Cancer
Triple Negative Breast Cancer
Endometrial Carcinoma
Soft Tissue Sarcoma
Keywords: Cancer
Oncology
Phase I
Gemcitabine
Carboplatin
MM-310
EphA2
Ephrin A2
Solid tumors
urothelial carcinoma
gastric carcinoma
squamous cell carcinoma of the head and neck
ovarian cancer
pancreatic ductal adenocarcinoma
prostate adenocarcinoma
non-small cell lung cancer
small cell lung cancer
triple negative breast cancer
endometrial carcinoma
soft tissue sarcoma
Merrimack
Lead sponsor: Merrimack Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2017-03-10
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.


Eligibility criteria: Inclusion Criteria:

* Must have one of the following cancers, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit

  * Urothelial carcinoma
  * Gastric/gastroesophageal junction/esophageal carcinoma (G/GEJ/E)
  * Squamous Cell Carcinoma of the Head and neck (SCCHN)
  * Ovarian cancer
  * Pancreatic ductal adenocarcinoma (PDAC)
  * Prostate adenocarcinoma (PAC)
  * Non-small cell lung cancer (NSCLC)
  * Small cell lung cancer (SCLC)
  * Triple negative breast cancer (TNBC)
  * Endometrial carcinoma
  * Soft tissue sarcoma subtypes except GIST, desmoid tumors and pleomorphic rhabdomyosarcoma
* Able to provide informed consent, or have a legal representative able and willing to do so
* ≥ 18 years of age
* Availability of a cancerous lesion amenable to biopsy and willing to undergo a pre-treatment biopsy
* ECOG Performance Status of 0 or 1
* Adequate bone marrow reserve as evidenced by:

  * ANC \> 1,500/µl (unsupported by growth factors) and
  * Platelet count \> 100,000/µl
  * Hemoglobin \> 9 g/dL
* Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits
* Adequate hepatic function as evidenced by:

  * Serum total bilirubin ≤ ULN
  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.
  * Alkaline phosphatase ≤ 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
  * In case alkaline phosphatase is \>2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 x ULN
* Adequate renal function as evidenced by a serum/plasma creatinine \< 1.5 x ULN
* Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
* Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.

Exclusion Criteria:

* Prior treatment with docetaxel within 6 months of study enrollment
* Pregnant or lactating
* Treatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirin
* Any evidence of hematemesis, melena, hematochezia, ≥ grade 2 hemoptysis, or gross hematuria
* Any history of hereditary bleeding disorders
* Presence of an active infection or with an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled
* Known CNS metastases
* Known hypersensitivity to the components of MM-310, or docetaxel
* Prior treatment with MM-310
* Received treatment, within 28 days or 5 half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade 1 or baseline
* Received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-310
* Received any anti-cancer drug known to have anti-VEGF/VEGFR activity within a period of 5 half-lives of this drug (e.g. 100 days for bevacizumab, 75 days for ramucirumab) prior to the first scheduled dose of MM-310
* Clinically significant cardiac disease, including: NYHA Class III or IV congestive heart failure, unstable angina, acute myocardial infarction within six months of planned first dose, arrhythmia requiring therapy (including torsades de pointes, with the exception of extrasystoles, minor conduction abnormalities, or controlled and well treated chronic atrial fibrillation)
* Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
* Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants
* Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310
* Concomitant use of strong inhibitors of CYP3A
* Patients with peripheral neuropathy of grade 2 or higher

Primary outcomes:
measure: Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.
timeFrame: 18 months
Secondary outcomes:
measure: Serum levels of analytes that comprise MM-310
timeFrame: 18 months
measure: Adverse event profile using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
timeFrame: 18 months
measure: Presence of human anti-human antibodies to MM-310
timeFrame: 18 months
measure: Objective responses based on RECIST v1.1 or other relevant criteria
timeFrame: 18 months
measure: Disease Control Rate
timeFrame: 18 months
measure: Progression Free Survival
timeFrame: 18 months
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Honor Health
state: Arizona
city: San Francisco
country: United States
facility: University California San Francisco
state: California
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Merrimack
name: Vasileios Askoxylakis, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. J Control Release. 2019 Sep 28;310:47-57. doi: 10.1016/j.jconrel.2019.08.006. Epub 2019 Aug 7.